TIDMONT
RNS Number : 9633Z
Oxford Nanopore Technologies plc
19 May 2023
Oxford Nanopore Technologies plc
London Calling Technology Update
Breakthrough technology performance generates richer information
for research and clinical analyses, and pathway to enabling
sequencing by anyone, anywhere
19 May 2023
Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"
or the "Company"), the company delivering a new generation of
Nanopore-based molecular sensing technology, presented breakthrough
performance data and new platform updates, including direct RNA
sequencing to support the emergence of RNA-based therapies, at the
Company's annual London Calling customer conference, held between
17 and 19 May 2023. Technology updates included:
Record-breaking performance and rapid sequencing, across the
nanopore sequencing platform:
Following the early access rollout of "Q20+" chemistry in 2022,
Oxford Nanopore sequencing technology has now broken records in
performance, providing more biological information than traditional
platforms, rapidly and at any scale. The platform now enables the
characterisation of telomere-to-telomere genomes, the sequencing of
single nucleotide variants (SNVs) as well as, or better, than
traditional technologies, in addition to the characterisation of
structural variation, complex copy number variants and real-time
gold standard methylation. This year "Q20+" chemistry moved from
early access to released stage.
-- Improved performance: While the latest "Q20+" sequencing
performance using the Simplex method continues to consistently
deliver high performance for most genomic applications, the
technology update included record-breaking performance data for
more challenging projects using Duplex. Duplex exceeds Q30/99.9%
single molecule accuracy irrespective of read length and will
become more widely available in a controlled commercial launch.
-- Richer data: The Company highlighted an expanded machine
learning model to enable real-time, high-accuracy epigenetic
insights in all contexts, including plants and bacteria, delivering
on the promise to sequence any DNA modification in any genome.
Pipeline: enabling accessible, distributed sequencing for
anyone, anywhere
Oxford Nanopore continues to innovate towards a new future of
near-sample, real-time, low-cost technology that can characterise
biological samples in any environments from clinics to factories to
classrooms.
-- High-output, small format: The PromethION 2 Solo rollout
continues, opening up new high-output sequencing possibilities with
compact form factor. Developer access to the PromethION 2i, with
integrated compute and screen, starts now and will continue through
the year.
-- New MinION - with iPad [i] connectivity: The MinION sequencer
has been revamped for the first time since 2015 and will continue
to enable a broad scientific community to take control of their
high-performance experiments, rapidly and in any environment. The
new MinION MkID will also offer easy seamless connection to an iPad
Pro, enabling it to use all the latest features including long
battery life, accelerated processing, 5G mobile connectivity and
more. Developer access starts later this year.
-- Smaller formats: In development and now showing "Q20+"
sequencing, a new, small and low-power chip (application specific
integrated circuit - ASIC) will further drive the ability to
analyse anything, anywhere. This new ASIC will underpin a new
family of lower-cost, lower-power devices, including the MinION
MkII while the standard MinION ASIC is also being revamped to
deliver data more quickly.
Direct RNA sequencing launch, available in Q3 2023
RNA, the messenger molecule that carries genetic information
from DNA and directs the synthesis of proteins, has traditionally
been sequenced by conversion to cDNA. New understanding of RNA's
functional significance - and related emergence in RNA-based
therapies including vaccines - has underscored the importance of
RNA-related research. Oxford Nanopore is the first to enable direct
sequencing of the native molecule, and in doing so reveals more
biology including RNA base modifications.
-- New RNA chemistry: Oxford Nanopore has introduced a new kit
and flow cell for direct RNA sequencing for increased accuracy and
output, with the potential to unlock a new field of biological
analysis. This update will enable significant advancements in the
RNA research market alongside novel applications of direct single
molecule sensing such as mRNA vaccine research, where non-natural
RNA bases used in their development need to be sequenced. Single
molecule raw-read accuracy has increased significantly, while
output has improved 3-4x compared to existing Oxford Nanopore RNA
sequencing chemistry.
Simplifying products and workflows to support broader usage
To support different users taking advantage of nanopore
sequencing, innovations are being introduced to simplify and make
more accessible the end-to-end sequencing process. These includes
provision of easy-to-use data analysis tools in EPI2ME, the
analytics tool set provided by Oxford Nanopore.
-- Easier interface to support more applications: EPI2ME
supports increasingly broad applications, from infectious disease,
biopharma quality control testing, human variations and single
cell. This enhanced interface equips users at all levels of
expertise with the information they need, wherever they are. New
features also include the ability to run on local hardware or
seamlessly integrate with cloud compute.
Pipeline: enabling ultra-high output, high-quality nanopore
sequencing
The PromethION 48 is already capable of delivering nearly 10,000
genomes per year, at two human genomes per flow cell, from $345 per
genome[ii]. Oxford Nanopore highlighted improvements to high-output
sequencing with the PromethION line to support users with larger
programmes, large sample numbers, or service providers in
high-output applications.
-- Increased output: The Company highlighted the immense
headroom still available in the platform that will be delivered
overtime utilising new pipeline enzymes (that pass DNA through a
nanopore faster), for increased output and improvements to run
buffers. With greater speeds there is the potential to deliver as
many as four human genomes from a single PromethION Flow Cell and
up to 20,000 genomes per year.
Replay of the t echnology update presentation
A written summary and video replay of the technology talk can be
accessed on the Oxford Nanopore website at:
https://nanoporetech.com/oxford-nanopore-london-calling-23-technology-update
Analyst and Investor Call
On Monday, 22 May 2023, at 3pm BST/10am EDT , Gordon Sanghera,
Chief Executive Officer and Rosemary Sinclair Dokos, SVP Product
and Programme Management will host a webcast and conference call
with analysts and investors to discuss the technology update
session from London Calling and address questions.
The webcast can be accessed on Oxford Nanopore's website at
https://nanoporetech.com/about-us/investors/reports or via this
link . The webcast will be recorded and a replay will be available
via the same link shortly after the event.
For conference call details please contact
ir@nanoporetech.com
[S]
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Teneo (communications adviser to the Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest
benefits to society through enabling the analysis of anything, by
anyone, anywhere. The company has developed a new generation of
nanopore-based sensing technology for real-time, high-performance,
accessible and scalable analysis of DNA and RNA. The technology is
used in more than 120 countries to understand the biology of humans
and diseases such as cancer, plants, animals, bacteria, viruses and
whole environments. Oxford Nanopore Technologies products are
intended for molecular biology applications and are not intended
for diagnostic purposes. www.nanoporetech.com
Forward-looking statements
This announcement contains certain forward-looking statements.
For example, statements regarding expected revenue growth and
profit margins are forward-looking statements. Phrases such as
"aim", "plan", "expect", "intend", "anticipate", "believe",
"estimate", "target", and similar expressions of a future or
forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future
business and financial performance and financial condition, and by
definition address matters that are, to different degrees,
uncertain. Our results could be affected by macroeconomic
conditions, the COVID-19 pandemic, delays in our receipt of
components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products
or accelerated adoption of pathogen surveillance. These or other
uncertainties may cause our actual future results to be materially
different than those expressed in our forward-looking
statements.
Notes
Release phases:
1 Developer access: Trial release of new innovations to a small
group of developers to confirm functionality and explore early use
cases. Available by request only.
2 Early access: All customers have access to the latest
innovation. Products are available to order in the main or private
store. Products are subject to availability and regular
changes.
3 Released: Products are stocked, available to all customers.
Iterations can still be expected but are more controlled with one
to three months change notifications.
4 Fully released: These products are mature with users receiving
change notifications three to six months in advance.
[i] iPad and iPad Pro are trademarks of Apple Inc.
[ii] Indicative price includes instrument, flow cells and
sequencing kits.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDNKFBKNBKBCPD
(END) Dow Jones Newswires
May 19, 2023 02:00 ET (06:00 GMT)
Oxford Nanopore Technolo... (LSE:ONT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Nanopore Technolo... (LSE:ONT)
Historical Stock Chart
From Apr 2023 to Apr 2024
